SCHEMBL6086476

SCHEMBL6086476

CC(=O)Nc1ccc(-c2n[nH]cc2-c2nc3ccccc3o2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.70
NPC1 O15118 9/20 0.70
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
SMN1; SMN2 Q16637 6/20 0.52
KDM4E B2RXH2 5/20 0.52
ALDH1A1 P00352 5/20 0.52
POLB P06746 3/20 0.52
CASP3 P42574 3/20 0.52
SENP7 Q9BQF6 3/20 0.52
SENP8 Q96LD8 2/20 0.52
SENP6 Q9GZR1 2/20 0.52
MAPT P10636 9/20 0.52
HPGD P15428 5/20 0.52
HTT P42858 2/20 0.52
LMNA P02545 1/20 0.52
RCE1 Q9Y256 1/20 0.52
TP53 P04637 3/20 0.51
HSD17B10 Q99714 3/20 0.51
NFKB1 P19838 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085267 0.89 NPC1 (0.55) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6086529 0.89 NPC1 (0.54) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6084882 0.88 KDM4E (0.59) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6086017 0.87 ALDH1A1 (0.58) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6085063 0.86 NPC1 (0.52) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6085362 0.86 NPC1 (0.52) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6086600 0.86 MAPT (0.56) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6084922 0.86 RAB9A (0.51) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6084815 0.86 MAPT (0.53) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6085407 0.85 NPC1 (0.51) RAB9ANPC1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 RAB9A 2584/4885NPC1 4031/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.